BR112021023927A2 - Composto, e, composição farmacêutica - Google Patents

Composto, e, composição farmacêutica

Info

Publication number
BR112021023927A2
BR112021023927A2 BR112021023927A BR112021023927A BR112021023927A2 BR 112021023927 A2 BR112021023927 A2 BR 112021023927A2 BR 112021023927 A BR112021023927 A BR 112021023927A BR 112021023927 A BR112021023927 A BR 112021023927A BR 112021023927 A2 BR112021023927 A2 BR 112021023927A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
same
provides
present
Prior art date
Application number
BR112021023927A
Other languages
English (en)
Portuguese (pt)
Inventor
Akishi Ninomiya
Hayato Nishiyama
Hiroyoshi Kawada
Kazuhiro Onuma
Ken-Ichi Komori
Kousuke Morishita
Naoya Kinoshita
Sayaka OGI
Tomio Kimura
Yukinori Wada
Yuusuke Shiraishi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of BR112021023927A2 publication Critical patent/BR112021023927A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112021023927A 2019-05-31 2020-05-29 Composto, e, composição farmacêutica BR112021023927A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019102529 2019-05-31
PCT/JP2020/021426 WO2020241853A1 (ja) 2019-05-31 2020-05-29 ベンゾトリアゾール誘導体

Publications (1)

Publication Number Publication Date
BR112021023927A2 true BR112021023927A2 (pt) 2022-02-08

Family

ID=73553193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023927A BR112021023927A2 (pt) 2019-05-31 2020-05-29 Composto, e, composição farmacêutica

Country Status (11)

Country Link
US (1) US12559504B2 (cg-RX-API-DMAC7.html)
EP (1) EP3978073B1 (cg-RX-API-DMAC7.html)
JP (1) JP7524899B2 (cg-RX-API-DMAC7.html)
KR (1) KR102978107B1 (cg-RX-API-DMAC7.html)
CN (1) CN114174289B (cg-RX-API-DMAC7.html)
AU (1) AU2020283361B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023927A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142295A1 (cg-RX-API-DMAC7.html)
ES (1) ES3047102T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021014680A (cg-RX-API-DMAC7.html)
WO (1) WO2020241853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN113024399B (zh) * 2021-03-11 2022-09-09 华东理工大学 药物中间体化合物及其制备方法、应用
KR102994906B1 (ko) * 2022-01-14 2026-07-24 주식회사 대웅제약 Sglt 저해제의 합성에 유용한 중간체의 제조 방법
CA3256688A1 (en) * 2022-04-28 2025-04-22 Daiichi Sankyo Company, Limited BENZOTRIAZOLE COMPOUND
WO2023210740A1 (ja) * 2022-04-28 2023-11-02 第一三共株式会社 ベンゾチオフェン化合物
EP4696692A1 (en) * 2023-06-19 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
LT3307739T (lt) * 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
KR20190088404A (ko) 2016-12-06 2019-07-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
WO2019116230A1 (en) 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
WO2019116231A1 (en) * 2017-12-11 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
US11643407B2 (en) 2018-05-23 2023-05-09 Glaxosmithkline Intellectual Property Development Limited Indanes as NRF2 activators
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
UA127872C2 (uk) 2018-12-05 2024-01-31 Скохія Фарма, Інк. Макроциклічна сполука та її застосування
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
WO2021002473A1 (ja) 2019-07-03 2021-01-07 千寿製薬株式会社 Nrf2活性化化合物
AU2021226994A1 (en) 2020-02-28 2022-09-08 Les Laboratoires Servier New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
AU2020283361B2 (en) 2025-11-27
CN114174289A (zh) 2022-03-11
US20220259223A1 (en) 2022-08-18
US12559504B2 (en) 2026-02-24
CA3142295A1 (en) 2020-12-03
WO2020241853A1 (ja) 2020-12-03
ES3047102T3 (en) 2025-12-03
EP3978073A4 (en) 2023-07-12
MX2021014680A (es) 2022-04-06
CN114174289B (zh) 2025-03-07
KR20220016124A (ko) 2022-02-08
EP3978073B1 (en) 2025-10-15
JP7524899B2 (ja) 2024-07-30
KR102978107B1 (ko) 2026-06-16
EP3978073A1 (en) 2022-04-06
JPWO2020241853A1 (cg-RX-API-DMAC7.html) 2020-12-03
EP3978073C0 (en) 2025-10-15
AU2020283361A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
WO2019191092A8 (en) Compounds for treating huntington's disease
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
WO2018226622A8 (en) Compounds for treating huntington's disease
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
BR112018071093A2 (pt) composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
WO2017100726A8 (en) Methods for treating huntington's disease
BR112018070859A2 (pt) degradantes da proteína de bet
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
GEAP202215303A (en) Chromane monobactam compounds for the treatment of bacterial infections
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
MX2021014680A (es) Derivado de benzotriazol.
BR112022025613A2 (pt) Novo inibidor de secreção de ácido e uso do mesmo
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112021011325A2 (pt) Derivados de rapamicina
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA202090068A1 (ru) Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
BR112018074985A2 (pt) composições antibacterianas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UBE CORPORATION (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]